COVID-19 vaccine Covaxin update: Bharat Biotech gets DCGI clearance for phase II trials

By: |
September 6, 2020 11:54 AM

Moving ahead with the testing of vaccines for the novel Coronavirus, Bharat Biotech will start the second phase of human clinical trials of its indigenously developed Covaxin in the coming week.

COVAXIN vaccine latest news, COVAXIN trial, COVAXIN vaccine, COVAXIN launch, COVAXIN covid 19 vaccine, COVAXIN launch date, COVAXIN results, Coronavirus vaccine, Coronavirus vaccine updates, Coronavirus vaccine in India, Coronavirus vaccine status, Coronavirus vaccine tracker, Coronavirus vaccine trialsCovaxin is considered as the country’s most promising one and is a frontrunner among COVID-19 vaccines.

Moving ahead with the testing of vaccines for the novel Coronavirus, Bharat Biotech will start the second phase of human clinical trials of its indigenously developed Covaxin in the coming week. It has received clearance from the regulator body—Drugs Controller General of India, according to a report by The Indian Express. The report said that the subject expert committee (SEC), after evaluating the request to begin the advanced phase of COVID-19 vaccine trials, has recommended that the trial will be conducted on 380 participants. The company has been notified of this in a letter dated September 3 by Joint Drugs Controller Dr. S Eswara Reddy.

It is to note that Covaxin is known as an “inactivated” vaccine that will work upon injecting doses of the virus that are not active, and will not pose any threat to humans. However, this will enable the body to build antibodies against it. In the first stage of vaccine testing, the focus was on the safety of healthy participants. With the beginning of phase II trials, the effectiveness of vaccines will be mapped. In the third and last phase of vaccine trials, the safety and efficacy of vaccines will be checked in a large scale population in the country.

According to the report, the first phase of the Covaxin trial was done with 375 participants from across 12 sites. A PTI report citing Dr Rao noted that blood samples collected from the volunteers showed the level of antibodies formed, thus indicating the effectiveness of Covaxin. Further, there have been no side effects in the volunteers during the first phase of trials.

The vaccine is considered as the country’s most promising one and is a frontrunner among COVID-19 vaccines. Meanwhile, Zydus Cadila and Serum Institute of India have already started conducting phase II trials for their vaccine candidates ZyCoV-D and Covishield (by Oxford-AstraZeneca) in India.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Unlock 5 guidelines: Cinema halls to open! Check what’s allowed from October 15
2Maharashtra Lockdown extended till October 31; Hotels, bars to operate from 5th with 50% capacity
3Maharashtra Governor Bhagat Singh Koshyari felicitates health workers for COVID-19 treatment